The quality of life for hundreds of women with advanced ovarian cancer is set to improve with an effective new drug treatment listed on the PBS.
A drug that provides quality of life for women who have an inherited form of advanced ovarian cancer has been listed on the Pharmaceutical Benefits Scheme, offering a ray of hope in the battle against the deadly disease.
The PBS listing of Lynparza (olaparib), the first oral prescription medicine for women with BRCA-mutated advanced ovarian cancer, has been heralded as the “most significant development in the past 30 years” in treatment…read the full story and watch the report here.